DOI: 10.1016/j.isci.2026.115716

Resource: (Cell Signaling Technology Cat# 2541, RRID:AB_2174466)

Curator: @scibot

SciCrunch record: RRID:AB_2174466

What is this?

DOI: 10.1016/j.isci.2026.115716

Resource: (Cell Signaling Technology Cat# 3528, RRID:AB_2160882)

Curator: @scibot

SciCrunch record: RRID:AB_2160882

What is this?

DOI: 10.1016/j.isci.2026.115716

Resource: (Sigma-Aldrich Cat# V9131, RRID:AB_477629)

Curator: @scibot

SciCrunch record: RRID:AB_477629

What is this?

DOI: 10.1016/j.isci.2026.115716

Resource: RRID:AB_2291558

Curator: @scibot

SciCrunch record: RRID:AB_2291558

What is this?

DOI: 10.1016/j.isci.2026.115716

Resource: (BD Biosciences Cat# 610467, RRID:AB_2128060)

Curator: @scibot

SciCrunch record: RRID:AB_2128060

What is this?

DOI: 10.1016/j.isci.2026.115716

Resource: (Cell Signaling Technology Cat# 8556, RRID:AB_10891442)

Curator: @scibot

SciCrunch record: RRID:AB_10891442

What is this?

DOI: 10.1016/j.isci.2026.115716

Resource: (Jackson ImmunoResearch Labs Cat# 111-035-144, RRID:AB_2307391)

Curator: @scibot

SciCrunch record: RRID:AB_2307391

What is this?

DOI: 10.1016/j.isci.2026.115716

Resource: (Cell Signaling Technology Cat# 4848, RRID:AB_10694415)

Curator: @scibot

SciCrunch record: RRID:AB_10694415

What is this?

DOI: 10.1016/j.isci.2026.115716

Resource: (Jackson ImmunoResearch Labs Cat# 115-035-068, RRID:AB_2338505)

Curator: @scibot

SciCrunch record: RRID:AB_2338505

What is this?

DOI: 10.1016/j.isci.2026.115716

Resource: RRID:AB_3698765

Curator: @scibot

SciCrunch record: RRID:AB_3698765

What is this?

DOI: 10.1016/j.isci.2026.115716

Resource: (Sigma-Aldrich Cat# A5979, RRID:AB_476749)

Curator: @scibot

SciCrunch record: RRID:AB_476749

What is this?

DOI: 10.1016/j.celrep.2026.117557

Resource: (Thermo Fisher Scientific Cat# A-31572, RRID:AB_162543)

Curator: @scibot

SciCrunch record: RRID:AB_162543

What is this?

DOI: 10.1016/j.celrep.2026.117557

Resource: (Molecular Probes Cat# A-11097, RRID:AB_2314332)

Curator: @scibot

SciCrunch record: RRID:AB_2314332

What is this?

DOI: 10.1016/j.celrep.2026.117557

Resource: (Thermo Fisher Scientific Cat# A-21235, RRID:AB_2535804)

Curator: @scibot

SciCrunch record: RRID:AB_2535804

What is this?

DOI: 10.1016/j.celrep.2026.117557

Resource: (Santa Cruz Biotechnology Cat# sc-5261, RRID:AB_627770)

Curator: @scibot

SciCrunch record: RRID:AB_627770

What is this?

DOI: 10.1016/j.celrep.2026.117557

Resource: (Molecular Probes Cat# A-11017, RRID:AB_143160)

Curator: @scibot

SciCrunch record: RRID:AB_143160

What is this?

DOI: 10.1016/j.celrep.2026.117557

Resource: (Proteintech Cat# 10077-1-AP, RRID:AB_2133977)

Curator: @scibot

SciCrunch record: RRID:AB_2133977

What is this?

DOI: 10.1016/j.celrep.2026.117557

Resource: (Roche Cat# 11814460001, RRID:AB_390913)

Curator: @scibot

SciCrunch record: RRID:AB_390913

What is this?

DOI: 10.1016/j.celrep.2026.117557

Resource: (Abcam Cat# ab79352, RRID:AB_2042832)

Curator: @scibot

SciCrunch record: RRID:AB_2042832

What is this?

DOI: 10.1016/j.celrep.2026.117557

Resource: RRID:AB_2200601

Curator: @scibot

SciCrunch record: RRID:AB_2200601

What is this?

DOI: 10.1016/j.celrep.2026.117557

Resource: (Santa Cruz Biotechnology Cat# sc-56703, RRID:AB_2200715)

Curator: @scibot

SciCrunch record: RRID:AB_2200715

What is this?

DOI: 10.1016/j.celrep.2026.117508

Resource: (Abcam Cat# ab26721, RRID:AB_777726)

Curator: @scibot

SciCrunch record: RRID:AB_777726

What is this?

DOI: 10.1016/j.celrep.2026.117508

Resource: (ABclonal Cat# A2363, RRID:AB_2756439)

Curator: @scibot

SciCrunch record: RRID:AB_2756439

What is this?

DOI: 10.1016/j.celrep.2026.117508

Resource: (Millipore Cat# MABE1095, RRID:AB_2861387)

Curator: @scibot

SciCrunch record: RRID:AB_2861387

What is this?

DOI: 10.1016/j.celrep.2026.117508

Resource: (ABclonal Cat# AE028, RRID:AB_2769867)

Curator: @scibot

SciCrunch record: RRID:AB_2769867

What is this?

DOI: 10.1016/j.celrep.2026.117508

Resource: (ABclonal Cat# A2357, RRID:AB_2631278)

Curator: @scibot

SciCrunch record: RRID:AB_2631278

What is this?

DOI: 10.1016/j.celrep.2026.117508

Resource: (ABclonal Cat# AE001, RRID:AB_2770403)

Curator: @scibot

SciCrunch record: RRID:AB_2770403

What is this?

DOI: 10.1016/j.celrep.2026.117508

Resource: (Transgen Biotech Cat# HT801, RRID:AB_2922385)

Curator: @scibot

SciCrunch record: RRID:AB_2922385

What is this?

DOI: 10.1016/j.celrep.2026.117508

Resource: (Transgen Biotech Cat# HT101-01, RRID:AB_2832251)

Curator: @scibot

SciCrunch record: RRID:AB_2832251

What is this?

DOI: 10.1016/j.canlet.2026.218654

Resource: (RRID:CVCL_0063)

Curator: @scibot

SciCrunch record: RRID:CVCL_0063

What is this?

/💻/asus/🧊/me/📓/2026/6/1/4

https://bafybeieiiw7e233o2zhizww4eqvzvxzedceefpcvoix34aenywf77yxg7a.ipfs.dweb.link?filename=MIH%C3%81LY%20BABITS%EF%BC%9A%20FROM%20THE%20BOOK%20OF%20DISSATISFACTION%20%E2%80%A2%20Posthumous%20writing%20by%20Ern%C5%91%20Osv%C3%A1t%20%EF%BD%9C%20West%201908-1941%20%EF%BD%9C%20Handbook%20(14_06_2026%2009%EF%BC%9A47%EF%BC%9A39).html

discontent

can be certern the luring occurred by whatsapp string with mr. Nick, He knows the beating and kidnapping occurred

Just you are clear, the client holds these funds against balance of contract. Client was advised to come to supplier, purchase directly but refused. nothing Gary could do to proceed. It was later alleged the client did do some work with a tile person and funds may have advanced to that person, speculation only

April 7 is kidnapping day

MS Pui and her husband(do not know his name), Mr. Ley (pui's brother), one other unknown person and mr. Nick, the person whom lure me in

kidnapping occurred April 7 with meeting meeting at village office 10,,,,Ms Pui never showed on time, I left 10:30 ish

PMID: 33301989

A PIK3CG variant in the catalytic domain is a risk factor for some infection-induced heart issue?

PMID:38485815

Gene:CTLA4

HGNC:2505

Case#: 88 ITP patients

DiseaseAssertion: Immune thrombocytopenia

FamilyInfo: N/A

CasePresentingHPOs: N/A

CaseHPOFreeText: N/A

CaseNotHPOs: N/A

CaseNotHPOFreeText: N/A

CasePreviousTesting: Real-Time PCR with sequence-specific primers was used to assess the CTLA-4 genotype

GenotypingMethod: Real-Time PCR with sequence-specific primers was used to assess the CTLA-4 genotype.

PreviouslyPublished: No

Variant: NM_005214.5:c.49A>G

ClinVar: 16921

CAID: CA126974

gnomAD: 0.6450 https://gnomad.broadinstitute.org/variant/2-203867991-A-G?dataset=gnomad_r4

Variant: NC_000002.12:g.203874196G>A

ClinVar: 16922

CAID: CA11297605

gnomAD: 0.6078 https://gnomad.broadinstitute.org/variant/2-203874196-G-A?dataset=gnomad_r3

PMID:38634985

Gene:PIK3CD

HGNC:8977

[[AD_VCEP_Annotation_Protocol_Updated.pdf]]

Case#: 42 Chinese APDS1 patients (27 males and 15 females)

DiseaseAssertion: activated PI3Kδ syndrome 1(APDS1)

FamilyInfo: 42 patients from 41 different families in China (P3 and P11 were from one family)

CasePresentingHPOs: HP:0002205(Recurrent respiratory infections) HP:0002110(Bronchiectasis) HP:00027168(Lymphadenopathy) HP:0001744(Splenomegaly) HP:0002240(Hepatomegaly) HP:0002960(Autoimmunity) HP:0003496(Increased circulating IgM level) HP:0004315(Decreased circulating IgG level) HP:0003237(Increased circulating IgG level) HP:0003212(Increased circulating IgE level) HP:0002720(Decreased circulating IgA level) HP:0040218(Reduced natural killer cell count) HP:0005403(T lymphocytopenia) HP:0005407(Decreased proportion of CD4-positive helper T cells)

CaseHPOFreeText: Table 1 contains information of 42 patients. Immunological phenotype of cohort is summarized in Table 2.

CaseNotHPOs: N/A

CaseNotHPOFreeText: N/A

CasePreviousTesting: Whole-exome sequencing

GenotypingMethod: Whole-exome sequencing

PreviouslyPublished: No

Variant: NM_005026.5:c.3061G>A p.E1021K

ClinVar: 88675

CAID: CA577192

gnomAD: 8.475e-7 https://gnomad.broadinstitute.org/variant/1-9726972-G-A?dataset=gnomad_r4

Variant: NM_005026.5(PIK3CD):c.3074A>G p.Glu1025Gly

ClinVar: 422410

CAID: CA16617216

gnomAD: Variant is not present in gnomAD data

Variant: NM_005026.5(PIK3CD):c.1574A>G (p.Glu525Gly)

ClinVar: 582515

CAID: CA338303813

gnomAD: Variant is not present in gnomAD data

Variant: NM_005026.5(PIK3CD):c.1570T>A p.Tyr524Asn

ClinVar: Not present in ClinVar

CAID: CA338303802

gnomAD: Variant is not present in gnomAD data

PMID: 35021606

Gene: PIK3CD

HGNC: 8977

Note: This paper records a cohort in which 33% of PTCL-EBV tumors (3/9 tested, Table S12) had mutations in PIK3CD (specific mutations not reported).

PMID: 32681977

Gene: PIK3CD

HGNC: 8977

Case#: Lougaris_2020_case, male, 12 yo (onset), origin in romania

DiseaseAssertion: APDS

FamilyInfo: non-consanguinous

CasePresentingHPOs: rash HP:0000988 pruritus HP:0000989 arthritis HP:0001369 splenomegaly HP:0001744 fever HP:0001945 lymphoma HP:0002665 arthralgias HP:0002829 increased ferritin HP:0003281 hepatitis HP:0012115 desquamation HP:0040189 malaise HP:0033834 increaased effector memory CD4 T cells HP:0025625

CaseHPOFreeText: increased AST, lymphadenomegaly, presence of rare hemophagocytes in bone marrow, elevated effector memory CD8 T cells, impaired peripheral B cell distribution, increased glucose metabolism in lymph nodes and spleen, increased IgG-positive plasma cells in the germinal centre and in the interfollicular area

CaseNotHPOs: EBV HP:0031693 Cytomegalovirus (CMV) HP:0031692 Abnormal NK count HP:0040089

CaseNotHPOFreeText: Herpes virus type I and II, Human herpes virus 8 (HHV8)

CasePreviousTesting:

GenotypingMethod: NGS

PreviouslyPublished: NR

Variant: c.323G > T: p.R108L

ClinVarID: 636973

CAID:

gnomAD: 0.00002823 Admixed American (1/35426)

SupplementalData:

Note: rash followed by desquamation - possible eczma?

Experimental Assay

PMID: 33080915

Gene: PIK3CD

HGNC: 8977

PMID: 27596086

Gene: PIK3CD

HGNC: 8977

Case#: Hui_2016, female, 2 yo (presentation), origin NR

DiseaseAssertion: APDS

FamilyInfo: variants verified in patient's parents, found to be de novo. It is unclear if case 2 and case 4 are related or unrelated.

CasePresentingHPOs: recurrent respiratory infections, enlargement of lymph node, hepatosplenomegaly, decreased number of native CD4 + T cells, inverted CD4 + /CD8 + T cell ratio and increased IgM, decreased IgA, decreased IgG,

HP:0002205, HP:0002716, HP:0001433, HP:0002720, HP:0032218, HP:0033222, HP:0002720, HP:0003496

CaseHPOFreeText: cytomegalovirus (CMV) or Epstein-Barr virus (EBV) viremia

CaseNotHPOs: NR

CaseNotHPOFreeText: NR

CasePreviousTesting: NR

GenotypingMethod: WGS

PreviouslyPublished: NR

Variant: HOMOZYGOUS 3061G>A (E1021K)

ClinVarID: 88675

CAID: N/A

gnomAD: not found in v2.1.1

SupplementalData: unknown

Note: Full access to article denied. Info in annotation gathered from abstract. Also, please be advised the curator translated the article from Chinese to English, and mistranslations are possible.

PMID: 29673649

Gene: PIK3CD

HGNC: 8977

Case#: case_Kiyota_2018, female,1 yo (onset), Japanese ancestry reported

DiseaseAssertion: APDS + 22q13 deletion syndrome

FamilyInfo: de novo

CasePresentingHPOs: (HP:0001973, HP:0000969, HP:0011134, HP:0000123, HP:0000093, HP:0003073, HP:0004431, HP:0003493, HP:0020151, HP:0033604, HP:0001263, HP:0001290, HP:0000729, HP:0002463, HP:0001249, HP:0007021, HP:0012433

ITP systemic edema mild fever lupus nephritis proteinuria hypoalbuminemia decreased complement levels antinuclear antibody double strand DNA antibody wire-loop lesions in glomeruli delayed psychmotor development hypotonia autistic features language delay intellectual disability reduced sensitivity to pain poor social functioning

CaseHPOFreeText: positive staining for IgG, IgA, IgM, C3 and C1q and electron-dense deposits observed through renal biopsy, along with wire-loop lesions

CaseNotHPOs: (HP:0030882, 0010783, HP:0030880) coronary aneurysm butterfly erythema Raynaud's phenomenon

CaseNotHPOFreeText: dysmorphic features

CasePreviousTesting: G-band karyotyping + whole genome SNP microarray revealed 22q13 deletion syndrome

GenotypingMethod: WES

PreviouslyPublished:

Variant: NM_005026.3:c.1534C > T; p.(Arg512Trp)

ClinVarID: 1347382

CAID: CA577258

gnomAD: v2.1.1 Grpmax 0.00007392 (4/18252 alleles) East Asian population

SupplementalData:

PMID: 29800648

Gene: PIK3CD

HGNC: 8977

Case#: 1_Edwards_2019, F, 40 yo (report), white ethnicity reported

DiseaseAssertion: APDS

FamilyInfo: NR

CasePresentingHPOs: EBV + (HP:0430064)

CaseHPOFreeText: NR

CaseNotHPOs: CMV, Lymphoma

CaseNotHPOFreeText: NR

CasePreviousTesting: NR

GenotypingMethod: NR

PreviouslyPublished: Yes PMID: 28414062

Variant: PIK3CD c.371G>A, p.G124D

ClinVarID: 2733822

CAID: CA338300460

gnomAD: not found

SupplementalData:

Case#: 3_Edwards_2019, F, 60 yo (report), white ethnicity reported

DiseaseAssertion: APDS

FamilyInfo: NR

CasePresentingHPOs: EBV +, diffuse large B-cell lymphoma (HP:0430064, HP:0002665)

CaseHPOFreeText: NR

CaseNotHPOs: CMV, Lymphoma (HP:0430087)

CaseNotHPOFreeText: NR

CasePreviousTesting: NR

GenotypingMethod: NR

PreviouslyPublished: No

Variant: PIK3CD c.1573G>A p.E525K

ClinVarID: 132807

CAID: n/a

gnomAD: not found

SupplementalData:

Case#: 2_Edwards_2019, F, 12 yo (report), African American ethnicity reported

DiseaseAssertion: APDS

FamilyInfo: NR

CasePresentingHPOs: EBV + (HP:0430064)

CaseHPOFreeText: NR

CaseNotHPOs: CMV, Lymphoma (HP:0430087, HP:0002665)

CaseNotHPOFreeText: NR

CasePreviousTesting: NR

GenotypingMethod: NR

PreviouslyPublished: Yes PMID: 24165795

Variant: PIK3CD c.1002C>A, p.N334K

ClinVarID: 132806

CAID: CA156204

gnomAD: not found

SupplementalData:

Case#: 12, M, 5 y.o., Ethnicity: Indian.

CasePresentingHPOs: HP:0001945 (Fever), HP:0001824 (Weight loss), HP:0002716 (Lymphadenopathy/FHL), HP:0003212 (Increased circulating IgE level), HP:0002716 (Lymphadenopathy), HP:0009098 (Chronic oral candidiasis), HP:0002841 (Recurrent fungal infections), HP:0032326 (Methicillin-resistant Staphylococcus aureus infection), HP:0020271 (Increased lymph-node eosinophils), HP:0100827 (Lymphocytosis), HP:0003237 (Increased circulating IgG level), HP:0002090 (Pneumonia)

CaseHPOFreeText: Eosinophils 17%, fungal scrapes—positive. Methicillin-resistant Staphylococcus aureus pneumonia, oral candidiasis/Hyper IgE.

Suspected recurring pneumonia.

CaseNotHPOs: N/A.

CaseNotHPOFreeText: N/A.

CasePreviousTesting: N/A.

CaseMethod1: N/A.

CaseMethod2: N/A.

CaseGenotypingMethod: Sanger sequencing and NGS targeting a customized panel of genes.

Variant: NM_005026.5:c.2296G>A.

ClinVar: 846790.

CAID: CA577485.

gnomAD: 0.00001611. https://gnomad.broadinstitute.org/variant/1-9722305-G-A?dataset=gnomad_r4.

VariantEvidence: N/A.

CaseAddInfo: N/A.

CasePMIDs: N/A.

Case#: 11, M, Age of onset: <1 year. Ethnicity: Indian.

CasePresentingHPOs: HP:0002028 (Chronic diarrhea), HP:0004432 (Agammaglobulinemia), ORPHA:1572 (Common variable immunodeficiency), HP:0040218 (Reduced natural killer cell count), HP:0004315 (Decreased circulating IgG concentration), HP:0002720 (Decreased circulating IgA concentration), HP:0002850 (Decreased circulating total IgM)

CaseHPOFreeText: Proband has normal ferritin levels. Proband has abnormally low B cells (66), low IgG, IgA, IgM levels. Proband has abnormally low natural killer (NK) cell count.

CaseNotHPOs: N/A.

CaseNotHPOFreeText: N/A.

CasePreviousTesting: N/A.

CaseMethod1: N/A.

CaseMethod2: N/A.

CaseGenotypingMethod: Sanger sequencing and NGS targeting a customized panel of genes.

Variant: NM_005026.5:c.1394C>T.

ClinVar: 709503.

CAID: CA577186.

gnomAD: Frequency: 0.0004085. Link: https://gnomad.broadinstitute.org/variant/1-9720166-C-T?dataset=gnomad_r4.

VariantEvidence: N/A.

CaseAddInfo: N/A.

CasePMIDs: N/A.

wow that's right we shouldn't allow that only send a slack message about the diff https://n8n-wfs-prod.tomorrow.io/workflow/VdmdIGc0PDft89vi

Negative association

LIVE: Joe Van Cleave at Typewriter Muse

Attended in person 2026-06-13 at Typewriter Muse in Riverside, CA

remove.

I would imagine that these things would vary from person to person. I find that when posed with a possible outing with friends, I go through what we might do throughout the event. This planning creates expectations in my mind the, in the past, I have had to overcome disappointment at expectations not being met. These are considered negative interpersonal communications, from my perspective.

As a person with, what I believe, is a strong sense of self, I struggle occasionally when I experience anxiety related to external conflict and problem solving. This interpersonal communication going on in my head, and I'm sure others, can sometimes fight each other for dominance.

SE used .NET 4.8 but is cross platform e.g. available mac.

大多数人可能认为AI的'幻觉'主要是在创意生成或虚构内容中出现的问题。但作者使用'apparent'一词暗示，这些错误可能并非明显的虚构，而是以看似可信的方式出现，这挑战了人们对AI错误类型的认知，表明AI错误可能更加隐蔽且难以识别，即使在专业领域也是如此。

主流观点认为大型专业咨询公司如KPMG应该有严格的事实核查流程，能够确保发布报告的准确性。然而，这个标题暗示即使是顶级专业机构也可能被AI的'幻觉'误导，这挑战了人们对专业机构质量控制能力的信任，表明AI错误可能比我们想象的更普遍且更具欺骗性。

大多数人认为随着AI技术的发展，它应该越来越可靠，尤其是在分析自身领域的数据时。但作者通过KPMG撤回报告的案例，提出了一个反直觉的观点：即使是专业的AI系统也可能在分析AI相关数据时产生严重错误，这暗示了AI自我评估的不可靠性，挑战了人们对AI技术自我完善能力的普遍认知。

大多数人认为大型科技公司CEO通常推动技术开放和广泛访问，但这里暗示亚马逊CEO Jassy可能对Anthropic的AI模型提出了安全担忧，导致这些模型被限制访问。这挑战了科技领袖总是倡导技术开放的常规认知，表明即使是科技巨头的高管也可能采取保守立场。

stolen pictures

Quel noeud

pas "utilisateur". Dire au cas par cas

Quels deux audit ?

This is a very powerful statement since it goes deep into how human emotions work. We almost become ghosts after suffering trauma. We lose a part of us that keeps us alive. We slowly rebuild and feel alive again but it's almost like walking ghosts when you lose a loved one or go through a traumatic experience.

You can feel the writers emotions through this. It feels almost sad that the advent of AI is slowly disrupting and taking away originality from the craft. It feels like a slow death of something that is supposed to have a lot of soul and emotion.

I love how the author is almost sarcastic with this comment. We don't know his position on AI-related writing yet. He prompts us to think that the prompts are realistic and useful but then says this which seems counterintuitive.

I remember using this in school!

huh? Can someone explain this point?

I was wondering where this excerpt came from since it wasn't recognized at the top of the page before the reading

This is a great point of how tech can be beneficial to aid students in facilitating a demonstration of their knowledge and skills

another helpful breakdown of these very common literary devices!

This is a really helpful description of what an analogy/analogical approch is

This is a great point! I've learned a lot just from how my peers are thinking about the text we were reading and it made me think a bit deeper about my own perspective.

I understand this point, but I am questioning this a bit in relation to the previous statement that students are using technology to regurgitate information. How do we shift this mindset on how they are using tech?

How do we fix this problem? How do we get students to produce instead of reproduce?

suggests that we need to change the approach to educating students with these technologies

Learning objective!

Start from #5 Move to #4 Move to #2 Move to #1 Move to #12 Move to #13 Move to #8 Move to #7 Move to #4 Move to #3 Move to #9, going through #6 Move to #11, going through #10 Move to #7 Move to #5 Move to #6 Move to #10 Finish by moving to #7

introdução

This is the whole idea behind arts integration! The whole goal is to use art forms to better represent what it is that they're learning. This is one of the clearest definitions of ats integration that I've seen.

I like this clarification of what differentiation is not. It is not expecting teachers to be able to meet every single need of every single student simultaneously at all times. It simply means that teachers are trying to make learning as flexible as possible. I think this is an important distinction to understand.

È il più recente di tutta questa sezione

Recognizing the value of the academic disciplines, an interdisciplinary approach that considers multiple areas together is typically more meaningful than teaching content areas separately.

reply to u/someblokeonhere at https://www.reddit.com/r/typewriters/comments/1u4ftix/which_typewriter_had_the_best_font/

The vast majority of typewriters were sold with a traditional mono-spaced Courier-like face in either pica or elite pitch (often with incredibly generic names like "Royal Pica" or "Royal Elite". Usually for about $5 (on what was often a $100 purchase which is about $1,000 in today's money), you could custom select an alternate face which was often marketed as a way to make your correspondence more personalized. They tried to make it a selling point, but I suspect it wasn't much of one in actual practice, particularly at that mark up. Many companies sold an "Executive" typeface that was often in italic as a means of differentiating typewriters meant for executives rather than the standard faces secretaries used.

Lots of alternate faces were manufactured for specific purposes like banking, accounting, speechwriting, and schools and those were sold as selling points for those markets. Other related features like keysets and special characters were marketed at pharmacists, doctors, engineers/mathematicians/scientists, and libraries.

If you create an account on the typewriter database you'll see options in the main menu for downloading full versions of a variety of typographical catalogs. Ted Munk also has (lesser) photo scans of some of these on his blog.

https://www.reddit.com/r/typewriters/comments/1u4gbul/its_working/

I suspect they meant 6mm width on the fabric ribbon?

https://www.reddit.com/r/typewriters/comments/1u4gbul/its_working/

To create an account on the typewriter database, visit https://typewriterdatabase.com/register-today.php (Ted Munk manually approves new accounts within a day or two.)

Joe Van Cleave has a good intro video on using the database: https://www.youtube.com/watch?v=5K5m1W7KNW8

And you'll find some notes on photos for the TWdB here: https://boffosocko.com/2024/10/24/photos-of-typewriters-for-the-typewriter-database/

大多数人认为政府有权出于国家安全考虑暂停AI模型访问，但作者认为政府的行动缺乏透明度、公平性和技术依据。这挑战了政府监管的权威性，暗示即使出于国家安全，政府行为也应受到严格约束。

大多数人认为发现新模型的漏洞意味着其风险高于现有模型，但作者认为通过深度防御策略，Fable的风险与现有模型相当。这挑战了人们对新技术风险更高的普遍认知，暗示新模型不一定比旧模型更危险。

大多数人认为AI公司应该追求完美的安全防护，但作者坦承完美防护是不可能的。这挑战了AI安全领域的期望，即公司应该能够完全防止其模型被滥用，转而采用更现实的防御策略。

大多数人认为政府应该严格监管AI模型以确保安全，但作者认为这种监管标准会阻碍整个行业的发展。这挑战了监管与安全平衡的常规认知，暗示过度监管可能扼杀创新。

大多数人认为发现AI模型的漏洞是严重的安全问题，需要立即采取措施，但作者认为这些漏洞在其他公开模型中也存在，暗示政府的反应过度。这挑战了AI安全领域的共识，即任何漏洞都应被视为重大威胁。

test

Briefing : Renoncer à l'Idéal du Parent Parfait

Résumé Exécutif

Ce document analyse les paradoxes et les pressions inhérents à l'éducation positive, tels qu'explorés dans le podcast d'ARTE Radio.

Initialement perçue comme une méthode miracle pour garantir la paix domestique et l'épanouissement de l'enfant, l'éducation positive s'est transformée en une source de culpabilité intense pour les parents.

L'analyse révèle que ce courant, né d'une évolution historique légitime du statut de l'enfant, est aujourd'hui marqué par des malentendus marketing, une vulgarisation scientifique fallacieuse et une individualisation excessive des enjeux éducatifs.

Le passage d'une éducation autoritaire à un modèle d'optimisation du potentiel de l'enfant impose aux parents — et particulièrement aux mères — une charge mentale et logistique quasi insupportable, souvent déconnectée des réalités sociales et matérielles.

1. L'Évolution Historique : De l'Indifférence aux Droits de l'Enfant

Le statut de l'enfant a connu une mutation radicale en à peine plus d'un siècle, passant d'une force de travail négligée à un être de droits dont l'intérêt est supérieur.

• Fin du XIXe siècle : L'enfant est encore perçu comme un outil de production (travail dans les mines).

• Après-guerre et théories de l'attachement : Les travaux de psychiatres comme René Spitz sur l'hospitalisme démontrent que la survie physique ne suffit pas ; la "nourriture affective" est vitale pour le développement.

• 1989, La Convention internationale des droits de l'enfant : Un tournant majeur.

L'enfant devient un sujet de droit (choix des amis, religion, éducation).

Parallèlement, une série de devoirs nouveaux est assignée aux parents pour garantir l'exercice de ces droits.

2. Le Concept de "Potentiel" : Le Parent comme Tuteur de l'Optimisation

L'éducation positive ne se résume pas à la bienveillance ; elle s'ancre dans la psychologie positive visant à maximiser le potentiel de l'individu.

• Le parent "tuteur" : Le rôle n'est plus d'imposer un destin (reprendre la ferme, devenir avocat), mais de permettre à l'enfant de déployer tout son potentiel moteur, social et cognitif.

• Une exigence sans fin : Cette vision crée un vertige chez le parent : en fait-on assez ?

Si l'enfant a une potentialité infinie, toute limite imposée par le parent peut être perçue comme "castratrice".

• Le piège des activités : Les droits de l'enfant (ex: activités extrascolaires) se transforment en impératifs logistiques pour les parents (taxi, attente dans la voiture, repas tardifs), menant souvent à l'épuisement et aux tensions qu'on cherchait justement à éviter.

3. Le Malentendu de la "Paix des Ménages"

L'un des principaux moteurs de l'adhésion à l'éducation positive est la promesse d'une fin des conflits, une promesse souvent non tenue.

• L'enfant affirmé vs l'enfant sage : L'éducation positive vise à créer des êtres démocratiques qui s'affirment et revendiquent leurs goûts.

Le malentendu réside dans le fait que les parents espèrent des "enfants sages comme des images", alors que la méthode produit des enfants qui questionnent l'autorité.

• Le marketing des recettes : Des manuels vendent des astuces de communication (ex: dire "stop" au lieu de "non") comme des solutions miracles.

Lorsque ces techniques échouent face au "mur du réel" (contraintes horaires, fatigue), le parent se sent en échec personnel.

4. La Critique des Neurosciences et de la Vulgarisation Fallacieuse

Béatrice Kammerer souligne une dérive dans l'utilisation des données scientifiques pour valider les préceptes de l'éducation positive.

• L'épouvantail du cortisol : Certains discours affirment que la colère ou le refus du parent provoquent des dommages neurologiques irréversibles chez l'enfant via l'hormone du stress.

• Des sources décontextualisées : Ces affirmations s'appuient souvent sur des études animales où les sujets subissent des tortures (électrocutions, privation de nourriture), ce qui est sans commune mesure avec les interactions d'une famille non maltraitante.

Cette "pseudo-science" renforce une culpabilité paralysante chez les parents.

5. La Dimension Politique : L'Individualisation du Fardeau

Le sociologue Claude Martin et les expertes interrogées critiquent la transformation de la parentalité en une quête de performance individuelle, typique de l'idéologie néolibérale.

• Le "Parent hors-sol" : On demande au parent de s'auto-former (livres, stages, respiration ventrale) pour devenir parfait, sans jamais interroger le contexte social (rythmes de travail, manque de soutien collectif).

• Inversion de la pyramide de Maslow : Au lieu d'assurer d'abord les bases matérielles et sociales (l'infrastructure), on demande au parent de travailler sur son "self" (le sommet de la pyramide) pour être une source de bienveillance inépuisable.

• La réussite individuelle comme injonction : L'idée que "vous avez tout pour réussir si vous appliquez les bonnes méthodes" transforme chaque cri ou chaque moment de fatigue en un échec personnel honteux.

Citations Clés

"On n'est plus comme dans les générations d'avant des parents qui peuvent imposer... on doit en fait être des tuteurs qui permettent aux enfants de grandir." — Isabelle Roskam

"L'éducation positive, et ben c'est pas si positif que ça... l'enfer est pavé de bonnes intentions." — Delphine Saltel

"On travaille pas sur l'infrastructure comme diraient les marxistes, on travaille sur le top et c'est le self, le moi... C’est une formidable pression que de nous mettre dans cette situation." — Claude Martin

"J'avais l'impression à chaque fois de laisser une empreinte supplémentaire... que j’allais lui faire du mal neurologiquement... c’est terrible." — Émilie (mère)

Conclusion

Le document souligne que si les principes de non-violence et de respect de l'enfant sont indiscutables, leur application sous forme d'idéal de perfection individuelle est contre-productive.

Renoncer à être un parent parfait, c'est reconnaître que la parentalité est un exercice humain, faillible, et surtout un projet de société collectif qui ne peut reposer uniquement sur les épaules et la psychologie des individus.

Inclusion, Aidance et Moments de Vie : Concilier Personnalisation et Équité en Entreprise

Ce document de synthèse analyse les interventions et les retours d'expérience de la table ronde organisée par HR Technologies France, portant sur l'intégration des réalités personnelles (handicap, aidance, parentalité) dans la stratégie RH sans créer de sentiment d'injustice.

Synthèse de la Stratégie

L'enjeu central identifié est de soutenir les réalités de vie des collaborateurs tout en évitant la perception de favoritisme.

La réussite de ces politiques repose sur trois piliers : l'intégration de l'inclusion dans la stratégie économique globale, la mesure précise par la donnée et la formalisation par le dialogue social.

Les entreprises ayant adopté une approche centrée sur les "moments de vie" observent des gains significatifs en termes d'engagement (eNPS) et de réduction de l'absentéisme.

1. L'Inclusion comme Levier Stratégique et Économique

L'inclusion ne doit plus être traitée comme un sujet de communication "à part", mais comme un prisme à travers lequel toute l'activité de l'entreprise est repensée.

• Intégration au Business : L'inclusion doit influencer la conception même des produits et services (ex : accessibilité des sites internet, tests médicaux inclusifs).

• Sortir des "Mots Valises" : Il est impératif de dépasser les slogans publicitaires pour privilégier la parole des salariés et la co-construction.

• La Mesure comme Prérequis : Toute politique d'inclusion doit débuter par un diagnostic démographique précis.

• Données et CNIL : Contrairement aux idées reçues, il est possible de collecter des données sur l'appartenance ethnique ou l'orientation sexuelle si l'objectif est précis et l'enquête définie.

• Indicateurs : Analyser l'effectif selon les 26 critères de discrimination pour identifier "où le bas blesse" (ex : taux de femmes dans les comités de direction).

2. Handicap et Accessibilité : Le Modèle de la Continuité

Le succès des politiques de handicap repose sur la structuration à long terme et l'accessibilité universelle.

• Réseau de Référents : La mise en place d'un réseau local, régional et national permet de relayer les outils et d'adapter les actions au terrain.

• Accessibilité Numérique : Le recrutement doit s'appuyer sur des sites 100 % accessibles (conformes au RGAA), facilitant la navigation pour tous.

• Exemple de la Sécurité Sociale :

  • Progression du taux d'emploi direct de 5,5 % à 8,7 % en dix ans.

• Partenariat avec des acteurs technologiques (ex : Microsoft) pour des tutoriels sur l'accessibilité des documents internes.

3. La Problématique de l'Aidance et de la Parentalité

L'aidance est un enjeu massif (1 salarié sur 3 se considère aidant), mais complexe à adresser en raison du manque de temps et de l'auto-stigmatisation des concernés.

Prévenir le Sentiment d'Injustice

Pour éviter que les mesures de soutien ne soient perçues comme des faveurs indues, deux leviers sont essentiels :

• La Formalisation Juridique : Inscrire les droits (ex : maintien de salaire, congés aidants) dans des accords de branche ou d'entreprise.

Le statut "officiel" de l'aidant banalise l'absence et ne repose plus uniquement sur la solidarité de l'équipe, qui peut s'essouffler.

• L'Accompagnement concret : Mise en place de paniers de services et de portails digitaux dédiés.

4. Passer des "Moments RH" aux "Moments de Vie"

Une mutation profonde de la fonction RH est proposée : passer d'une gestion axée sur le cycle professionnel (recrutement, formation, fidélisation) à un accompagnement des événements personnels ayant un impact professionnel.

| Type de Moment | Exemples | | --- | --- | | Moments de Vie (51 identifiés) | Divorce, maladie, violences conjugales, deuil, déménagement, transition LGBT. | | Actions de Soutien Critiques | Logement d'urgence en 4h pour les victimes de violences conjugales via des partenariats avec des bailleurs sociaux. |

Levier Technologique et Managérial

• CRM des Moments de Vie : Utilisation de l'IA et de l'automatisation pour alerter les managers et les RH au bon moment, en leur fournissant les fiches pratiques et les ressources nécessaires.

• Équilibre d'Attention : Ne pas laisser le manager seul face à l'ajustement du cadre collectif ; les outils doivent lui servir "sur un plateau" les solutions pré-établies.

5. Résultats et Indicateurs de Performance (KPIs)

L'impact d'une politique de soutien aux moments de vie se mesure concrètement sur une période de 3 à 4 ans.

• Engagement (eNPS) : Progression spectaculaire constatée dans le secteur bancaire, passant de -34 à +43.

• Absentéisme : Réduction de 12 % à 7 %.

• Fidélisation : Chute du taux de démission de 6 % à 1,5 %.

• Climat Social : Transformation des "verbatims" critiques en remerciements envers la fonction RH.

6. Évolution du Modèle de Leadership

Pour pérenniser ces actions, la culture d'entreprise doit évoluer vers un modèle moins pyramidal :

• Leadership Partagé : Distinction entre le manager, le "Change Leader" (qui porte le changement sans lien hiérarchique) et le "Change Expert".

• Symétrie des Attentions : Appliquer aux collaborateurs les mêmes signatures relationnelles qu'aux clients (Rassurer, Valoriser, Porter intérêt, S'engager, Célébrer).

• Groupes de Ressources (ERG) : Responsabiliser les salariés à travers des groupes de pairs pour porter les actions d'inclusion de manière ascendante.

Non è malissimo, dice fondamentalmente che PCSK9 quando causa problemi è dovuta a una produzione cronica. Utile per confermare ulteriormente che non ci sono effetti avversi alla sua soppressione. Guarda le conclusioni

That explains it

Wtf does this mean

💻/asus/🧊/me/📓/2026/6/1/3/youtube.com grok-ai-ethiopean-bible-resurrection/

Elon Musk's Grok AI Was Asked About Jesus'Resurrection in the Ethiopian Bible—Its Answer Is Haunti

和刚才说的一样，你不需要长篇大论，只需要简单说明方案是什么，以及怎样一步步执行。大家都知道要从风险低的方向入手，对不对？

应该首先说明，遇到的问题，纯本地模型的优势劣势，纯云端模型的，内容应该是相对针对本地模型与云端模型结合的话题，建议从以下逻辑展开：

1. 问题背景：

   • 当前遇到的核心问题是什么？
   • 本地模型与纯云端模型的优缺点分析。
   • 为何需要两者结合使用？
   • 结合使用时的优势与劣势。

2. 痛点解决与合规分析：

   • 如何解决结合使用带来的劣势？
   • 劣势的分类探讨：
     • 法律层面的挑战。
     • 客户合同中保密协议的约束。

3. 调研重点与实施路径（关于POC）：

   • 明确共识：各方已知该方案无法一蹴而就，因此需要深度研究。
   • 核心重心：
     • 如何具体执行。
     • 合规的边界在哪里？
     • 法律与技术的具体问题有哪些？
     • 如何设计实验验证方案？

这种不用你说啊= = 谁都知道，直接阐述内容就可以

应该完全删去类似的描述，目的就是要呈现结果，可以给任何人看的

oh, I know that was possible - to choose expert based on the query rather than the tokens

some visulaizations (bar or donut or mosaic graph) would be helpful here

I don't htink this is a stochastic model? Perhaps an extension of this should give these (correlated?) distributions. ... Squiggle-type modeling

There should also be discplay of the actual equation behind the model, and a folding box or linked page explaining it in more detail

Maybe put this model at the top, after a short preamble?

Questo articolo è molto completo su credo tutti i temi che riguardano PCSK9 nella tesi, ottimissimo

Sembra un'ottima immagine

Statistic represents property of the sample!

From a freelancer's (Developer's) perspective, here's how these terms shake out. A few provisions tilt meaningfully against you, and several are worth understanding before you sign up. Payment risk is the biggest concern You only get paid if the Client pays first. Several clauses stack here:

Payment is contingent on Client funds. Section 10 says Developer payments are "contingent upon receipt of funds from Clients," and Section 13 confirms Lemon.io will never pay you out of its own pocket. If a Client doesn't fund their account, disputes the work, or does a chargeback, you may not be paid — or paid only partially and proportionally to what Lemon.io actually collected. You're paid by the 10th of the following month (Section 10), but "any payment may be received with a delay caused by the receiving party or its servicing bank" — a fairly open-ended delay allowance. Disputes cap your recovery. Section 17 means no payment is made for disputed services unless the dispute resolves in-platform, and Lemon.io itself is the arbiter whose decisions are "full and unchallenged."

The practical upshot: your cash flow depends on Lemon.io's collection from Clients, and you bear the downside of Client non-payment. You can't negotiate or compare your rate Section 10 prohibits discussing your hourly rate with other users — only with the Lemon.io team. That removes your ability to benchmark whether you're being paid competitively relative to peers on the platform. The non-compete locks you in Section 16 bars you from working directly with a Client off-platform without going through Lemon.io's hiring process and fee. Combined with the Client-side $14,000 / $20,000 placement fees (Sections 8 and 12), there's strong friction against converting a platform relationship into a direct one — even years later, since the Terms don't state a time limit on this restriction. You hand over broad rights to your content Section 22 grants Lemon.io a perpetual, irrevocable, royalty-free, transferable, sublicensable license to anything you submit through the platform, plus a waiver of "moral rights." Separately, Section 25 makes your client deliverables works-made-for-hire owned by the Client on full payment. Standard for marketplaces, but worth knowing your messages and submitted materials aren't fully your own once posted. Termination is at-will and one-sided Section 21 lets Lemon.io suspend or remove you "at any time for any or no reason at all," effective immediately, with no guarantee of rejoining. There's no reciprocal protection or notice period for you. Liability and disputes favor the platform If you ever have a claim against Lemon.io, Section 32 caps their total liability at $500, Section 29 waives your jury trial and class-action rights and forces Delaware arbitration, and Section 28 sets Delaware as the governing law and venue — potentially far from where you live, especially if you're an international developer. A few smaller things

Tax and compliance are entirely yours (Section 5). You're an independent contractor: no benefits, no withholding, and you indemnify Lemon.io if it's found liable for taxes related to you. Sanctions representations (Section 14) — you warrant you're not in a sanctioned region or on U.S. denied-party lists. Relevant if you're an international freelancer. The "never committed a felony" warranty in the Privacy Policy is an odd thing to be agreeing to as a factual representation.

What this means practically None of this is unusual for a developer marketplace — the structure (contingent pay, non-compete, broad license, arbitration) is industry-standard. But the combination of payment contingent on client funding, Lemon.io as sole dispute arbiter, and the $500 liability cap means your financial protection rests largely on trusting the platform's collection and dispute processes rather than on contractual guarantees. A reasonable freelancer's takeaway: it can be a legitimate source of work, but treat platform earnings as carrying real counterparty risk, keep your own records of hours and communications, and don't count on the contract itself to make you whole if a payment or dispute goes sideways. One thing I'd genuinely flag — I'm not your lawyer, and if you're weighing this as a meaningful income source or you're in a jurisdiction with strong worker-protection laws (much of the EU, for instance), it may be worth a quick consult, since some of these clauses (the non-compete scope, the misclassification setup) can interact with local law in ways that override what's written here.

DOI: 10.64898/2026.05.01.722324

Resource: (MMRRC Cat# 034848-JAX,RRID:MMRRC_034848-JAX)

Curator: @AleksanderDrozdz

SciCrunch record: RRID:MMRRC_034848-JAX

What is this?

DOI: 10.64898/2026.04.29.721673

Resource: RRID:Addgene_107738

Curator: @olekpark

SciCrunch record: RRID:Addgene_107738

What is this?

DOI: 10.64898/2026.04.29.721673

Resource: RRID:Addgene_112677

Curator: @olekpark

SciCrunch record: RRID:Addgene_112677

What is this?

DOI: 10.64898/2026.04.28.721509

Resource: RRID:Addgene_103005

Curator: @olekpark

SciCrunch record: RRID:Addgene_103005

What is this?

DOI: 10.64898/2026.04.28.721509

Resource: RRID:Addgene_83279

Curator: @olekpark

SciCrunch record: RRID:Addgene_83279

What is this?

DOI: 10.64898/2026.05.01.722089

Resource: (MMRRC Cat# 034829-JAX,RRID:MMRRC_034829-JAX)

Curator: @AleksanderDrozdz

SciCrunch record: RRID:MMRRC_034829-JAX

What is this?

DOI: 10.64898/2026.04.26.720914

Resource: RRID:Addgene_187441

Curator: @olekpark

SciCrunch record: RRID:Addgene_187441

What is this?

DOI: 10.64898/2026.02.24.707855

Resource: RRID:MMRRC_064016-UCD

Curator: @AleksanderDrozdz

SciCrunch record: RRID:MMRRC_064016-UCD

What is this?

DOI: 10.3390/toxics12090658

Resource: RRID:BDSC_3605

Curator: @bdscstockkeepers

SciCrunch record: RRID:BDSC_3605

What is this?

DOI: 10.3390/ijms27114994

Resource: (MMRRC Cat# 034829-JAX,RRID:MMRRC_034829-JAX)

Curator: @AleksanderDrozdz

SciCrunch record: RRID:MMRRC_034829-JAX

What is this?

DOI: 10.3390/ijms27114893

Resource: (TKG Cat# TKG 0205, RRID:CVCL_0027)

Curator: @evieth

SciCrunch record: RRID:CVCL_0027

What is this?

DOI: 10.3389/fphar.2026.1833813

Resource: (Novus Cat# NBP1-77368, RRID:AB_11018151)

Curator: @evieth

SciCrunch record: RRID:AB_11018151

What is this?

DOI: 10.3389/fimmu.2026.1759368

Resource: (Cell Signaling Technology Cat# 9496, RRID:AB_561381)

Curator: @evieth

SciCrunch record: RRID:AB_561381

What is this?

DOI: 10.1371/journal.pone.0350815

Resource: (Abcam Cat# ab8245, RRID:AB_2107448)

Curator: @evieth

SciCrunch record: RRID:AB_2107448

What is this?

DOI: 10.1371/journal.pone.0350815

Resource: (Abcam Cat# ab216144, RRID:AB_2927726)

Curator: @evieth

SciCrunch record: RRID:AB_2927726

What is this?

DOI: 10.1242/jcs.264460

Resource: RRID:BDSC_62545

Curator: @evieth

SciCrunch record: RRID:BDSC_62545

What is this?

DOI: 10.1242/jcs.264460

Resource: RRID:BDSC_9778

Curator: @evieth

SciCrunch record: RRID:BDSC_9778

What is this?

DOI: 10.1242/jcs.264460

Resource: RRID:BDSC_95282

Curator: @evieth

SciCrunch record: RRID:BDSC_95282

What is this?

DOI: 10.1242/jcs.264460

Resource: RRID:BDSC_9771

Curator: @evieth

SciCrunch record: RRID:BDSC_9771

What is this?

DOI: 10.1242/jcs.264460

Resource: RRID:BDSC_24616

Curator: @evieth

SciCrunch record: RRID:BDSC_24616

What is this?

DOI: 10.1242/dev.205143

Resource: (MMRRC Cat# 034748-UCD,RRID:MMRRC_034748-UCD)

Curator: @AleksanderDrozdz

SciCrunch record: RRID:MMRRC_034748-UCD

What is this?

DOI: 10.1186/s40478-026-02301-2

Resource: (RRID:CVCL_W559)

Curator: @evieth

SciCrunch record: RRID:CVCL_W559

What is this?

DOI: 10.1186/s13020-026-01433-w

Resource: (Santa Cruz Biotechnology Cat# sc-7480, RRID:AB_626729)

Curator: @evieth

SciCrunch record: RRID:AB_626729

What is this?

DOI: 10.1186/s13020-026-01433-w

Resource: (Millipore Cat# MAB374, RRID:AB_2107445)

Curator: @evieth

SciCrunch record: RRID:AB_2107445

What is this?

DOI: 10.1186/s13020-026-01433-w

Resource: (Millipore Cat# MAB377, RRID:AB_2298772)

Curator: @evieth

SciCrunch record: RRID:AB_2298772

What is this?

DOI: 10.1186/s13020-026-01433-w

Resource: (Millipore Cat# MAB1501, RRID:AB_2223041)

Curator: @evieth

SciCrunch record: RRID:AB_2223041

What is this?

DOI: 10.1159/000547041

Resource: RRID:Addgene_48140

Curator: @dhovakimyan1

SciCrunch record: RRID:Addgene_48140

What is this?

DOI: 10.1159/000547041

Resource: RRID:Addgene_48140

Curator: @dhovakimyan1

SciCrunch record: RRID:Addgene_48140

What is this?

DOI: 10.1159/000547041

Resource: (RRID:CVCL_3985)

Curator: @dhovakimyan1

SciCrunch record: RRID:CVCL_3985

What is this?

DOI: 10.1159/000547041

Resource: (JCRB Cat# JCRB0183, RRID:CVCL_3143)

Curator: @dhovakimyan1

SciCrunch record: RRID:CVCL_3143

What is this?

DOI: 10.1158/2767-9764.CRC-25-0619

Resource: (Thermo Fisher Scientific Cat# A-11012, RRID:AB_2534079)

Curator: @evieth

SciCrunch record: RRID:AB_2534079

What is this?

DOI: 10.1158/2767-9764.CRC-25-0280

Resource: Van Andel Institute Flow Cytometry Core Facility (RRID:SCR_022685)

Curator: @evieth

SciCrunch record: RRID:SCR_022685

What is this?

DOI: 10.1158/2767-9764.CRC-25-0280

Resource: Van Andel Institute Transgenics Core Facility (RRID:SCR_022914)

Curator: @evieth

SciCrunch record: RRID:SCR_022914

What is this?

DOI: 10.1158/2767-9764.CRC-25-0280

Resource: Van Andel Institute Optical Imaging Core Facility (RRID:SCR_021968)

Curator: @evieth

SciCrunch record: RRID:SCR_021968

What is this?

DOI: 10.1158/1055-9965.EPI-26-0156

Resource: LOCUSZOOM (RRID:SCR_009257)

Curator: @evieth

SciCrunch record: RRID:SCR_009257

What is this?

DOI: 10.1158/0008-5472.CAN-25-2893

Resource: RRID:Addgene_48743

Curator: @olekpark

SciCrunch record: RRID:Addgene_48743

What is this?

DOI: 10.1158/0008-5472.CAN-25-2893

Resource: RRID:Addgene_132777

Curator: @olekpark

SciCrunch record: RRID:Addgene_132777

What is this?

DOI: 10.1158/0008-5472.CAN-25-2893

Resource: RRID:Addgene_62988

Curator: @olekpark

SciCrunch record: RRID:Addgene_62988

What is this?

DOI: 10.1158/0008-5472.CAN-25-2893

Resource: RRID:Addgene_12260

Curator: @olekpark

SciCrunch record: RRID:Addgene_12260

What is this?